Collaborative Networks Driving Regulatory Transformation in Latin America
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
Since 1950 Argentia Laboratories has been dedicated to the production and marketing of pharmaceuticals, launching products that have become leading brands. Throughout its existence, Argentia has sustained steady growth becoming a model for Argentine pharmaceutical market. Their commitment to excellence and internationally strong reputation support their brands and ranks among the leading pharmaceutical companies in Argentina. Currently, Argentia has professional and highly trained technicians, with extensive advanced technical resources, facilities and equipment which they apply to physical-chemical, pharmaco-technical, microbiological and pharmacological control of all of their products. Medical, retail, administrative and marketing activities support their core capabilities, and a respect for life and ecological principles underpin the company’s daily operations.
NOVA ARGENTIA S.A.
Carlos Calvo 2764 4to Piso. (C1230AAT) C.A.B.A.
Tel: 5296-9350 – Fax: 5296- 9362
E-mail: info@argentia.com.ar – Web: www.argentia.com.ar
Facebook: /LaboratoriosArgentia – Twitter: @NovaArgentia
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
